Whitehawk Therapeutics raises $87.5M in PIPE, extends cash runway into H2 2028

Whitehawk Therapeutics, Inc.

• Sells 4.33M shares at $3.92/share and 17.99M pre-funded warrants at $3.9199/warrant.
• PIPE includes existing investors Avoro Capital, QVT, Coastlands, KVP, ADAR1, Acuta, StemPoint, Invus, and executives.
• Expected close May 14, 2026; net proceeds for working capital and ADC pipeline advancement.
• Cash runway extended into second half of 2028.
• Lock-up agreements for executives/directors: 60 days post-closing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.